| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 5.157 | 8.092 | 23.199 | 0 | 8.071 | 23.653 | 16.424 |
| Total Income - EUR | - | - | - | 5.158 | 8.092 | 23.199 | 1 | 8.071 | 23.653 | 16.424 |
| Total Expenses - EUR | - | - | - | 40 | 872 | 7.031 | 1.601 | 67 | 17.252 | 20.056 |
| Gross Profit/Loss - EUR | - | - | - | 5.119 | 7.220 | 16.168 | -1.600 | 8.004 | 6.401 | -3.632 |
| Net Profit/Loss - EUR | - | - | - | 4.964 | 6.977 | 15.490 | -1.600 | 7.762 | 5.377 | -3.829 |
| Employees | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Endogenesis Research Solutions S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 53 | 52 | 51 | 50 | 50 | 33.336 | 23.220 |
| Current Assets | - | - | - | 5.186 | 11.961 | 27.609 | 762 | 8.768 | 21.255 | 6.972 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 515 |
| Cash | - | - | - | 5.186 | 11.961 | 27.609 | 762 | 8.768 | 21.255 | 6.457 |
| Shareholders Funds | - | - | - | 5.007 | 11.887 | 27.152 | 691 | 8.455 | 13.806 | 9.900 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 232 | 126 | 509 | 121 | 364 | 40.785 | 20.291 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7020 - 7020" | |||||||||
| CAEN Financial Year |
7022
|
|||||||||
Comments - Endogenesis Research Solutions S.r.l.